Partnering with a major pharma to refine the market access strategy for a rare disease asset

We worked with senior executives of a pharma company to ensure launch readiness support of a drug in the immunology space. By creating an understanding of an asset’s clinical profile and competitive positioning, we helped to refine strategic communication materials to better demonstrate the value to all stakeholders in the HTA assessment and the pricing and reimbursement process. Facilitating cross-functional communication helped to ensure alignment based on real-world evidence needs for optimal treatment decision-making.